pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

5,458 stories · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1671Endpoints1316Fierce Biotech632BioSpace632BioPharma Dive494raps211onclive165fda recalls108fda medwatch
therapy area
allOncology11784Rare Disease2960Immunology2721Cardiology2405Pulmonology2054Hematology2004Vaccines1730Psychiatry & CNS1141
  • Former USAID Ebola adviser says lessons from 2014 are fading as new outbreak spreads in DRC and Uganda
    In October 2014 Susan Reichle served as a counselor to USAID in Washington, D.C., when the CDC launched its largest ever Ebola response. She contrasts that crisis with the current outbreak in the…
    STAT · 4mo agoNeutral↗ source
  • Biopharma workers earned $116,648 on average in 2025, about 30% above S&P 500 peers
    The Endpoints News pay analysis found that the average biopharma employee earned $116,648 in 2025. This figure reflects compensation across the sector for that year. Compared with the broader mark…
    Endpoints · 4mo agoPositive↗ source
← prev
page 179 of 219
next →
100
globenewswire health73
fda press56
Ophthalmology906
Endocrinology & Metabolism729
Pain702
Nephrology698
ADA ejects five diabetes experts for distributing editorial criticizing NIH research cuts
Security personnel removed five diabetes researchers from the American Diabetes Association's annual meeting in New Orleans after they handed out copies of an editorial that condemned recent federa…
STAT · 4mo agoNegative↗ source
  • Eli Lilly's 340B claims data deadline passes, sparking potential new dispute
    Eli Lilly set a deadline for hospitals to submit 340B drug‑pricing program claims data under its new policy. The deadline has now passed, and the company has not indicated what actions it will tak…
    Endpoints · 4mo agoRegulatoryNeutral↗ source
  • Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
    Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
    BioPharma Dive · 4mo agoRegulatoryNeutral↗ source
  • Federal alcohol study finds low-level drinking may raise disease risk, faces political pushback
    STAT’s Morning Rounds reported that a federally commissioned study on alcohol’s health effects was published today in an independent journal. The researchers concluded that even modest alcohol cons…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Biopharma CEOs see soaring compensation, new analysis to be discussed live
    Endpoints News released the first installment of its annual biopharma compensation project, breaking down the pay of the industry’s highest-earning CEOs. The company will host a Post-Hoc Live web…
    Endpoints · 4mo agoNeutral↗ source
  • Trump administration threatens fines for over 500 hospitals that fail to disclose pricing
    The Trump administration has warned more than 500 hospitals that they are not providing the public with basic pricing information, the Associated Press reported. Hospitals that fail to create a pl…
    STAT · 4mo agoRegulatoryNegative↗ source
  • K Health expands AI chatbot from symptom checker to hospital use
    K Health, a startup founded in 2016 as a symptom checking tool, is now deploying its AI chatbot within hospital environments. The shift follows a broader surge in AI driven virtual doctors that pa…
    Endpoints · 4mo agoPositive↗ source
  • NIH names John Powers III as acting director of NIAID amid leadership uncertainty
    The National Institutes of Health has appointed researcher John Powers III to serve as acting director of the National Institute of Allergy and Infectious Diseases (NIAID). Powers previously served…
    STAT · 4mo agoNeutral↗ source
  • Oura and Whoop add in-app virtual doctor visits, moving wearable data toward clinical use
    Wearable makers Oura and Whoop announced that users will soon be able to connect with doctors through their apps, allowing virtual consultations when a device flags a health concern. The new featu…
    STAT · 4mo agoNeutral↗ source
  • Trump-suppressed alcohol health study released, finds low-level drinking may raise disease risk
    A federal study on alcohol's health effects, commissioned by SAMHSA in 2023 to inform U.S. dietary guidelines, has finally been published in a scientific journal after being withheld by the Trump a…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Endpoints launches nominations for its 2026 Women in Biopharma project
    Endpoints announced that nominations are now open for its eighth annual Women in Biopharma initiative, which highlights contributions of women in the industry. The program, scheduled for 2026, see…
    Endpoints · 4mo agoPositive↗ source
  • NIH staff say leadership ignored dissent letter a year after Bethesda Declaration
    A new report released on the one‑year anniversary of the Bethesda Declaration says NIH leadership has largely ignored the concerns raised by staff in their open letter of dissent. The report, titl…
    STAT · 4mo agoNegative↗ source
  • STAT chooses to keep health care as two words despite AP stylebook shift
    The Associated Press updated its style guide in April, merging health care into the single word healthcare. The change sparked discussion among journalists and readers. At STAT, the editorial staf…
    STAT · 4mo agoNeutral↗ source
  • Roche commits $700 million to co-develop Nurix's BTK-degrading drug bexobrutideg
    Roche announced a partnership with Nurix Therapeutics to co-develop a protein-degrading therapy called bexobrutideg, which targets the BTK enzyme. Under the agreement, Roche will pay $700 million…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Lilly’s retatrutide data at ADA 2026 underscores its lead in obesity drug market
    The American Diabetes Association’s 2026 meeting highlighted a wave of new weight‑loss drug data as companies vie for a slice of a market dominated by Eli Lilly and Novo Nordisk. Lilly presented r…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • J&J to buy Firefly Bio for $1 billion to boost KRAS inhibitor program
    J&J announced Monday it will acquire biotech startup Firefly Bio for $1 billion, aiming to broaden its KRAS inhibitor portfolio. The move follows recent data from Revolution Medicines showing a KR…
    STAT · 4mo agoDealPositive↗ source
  • Tango to launch Phase 3 trial in pancreatic cancer after promising combo results
    Tango announced plans to begin a Phase 3 trial testing a combination therapy for pancreatic cancer. The decision follows data presented at the American Society of Clinical Oncology meeting, where…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • Roche to pay $700M upfront to Nurix for BTK degrader collaboration, deal up to $2.3B
    Roche announced a collaboration with Nurix Therapeutics to develop a BTK degrader for B cell malignancies. Roche will provide $700 million upfront, and the agreement could be worth up to $2.3 bill…
    Endpoints · 4mo agoDealPositive↗ source
  • Financing gaps keep $2 million gene therapies out of reach for many patients
    William Padula argues that the United States lacks the financial infrastructure to deliver ultra‑expensive gene therapies, even though they can cure diseases with a single dose. He notes that treat…
    STAT · 4mo agoNegative↗ source
  • Lilly shares safety data on next-gen obesity drug retatrutide; Revolution Medicines reports strong pancreatic cancer results
    Lilly provided new data that detail the safety and tolerability profile of its next-generation obesity therapy, retatrutide. The information adds to the growing body of evidence supporting the drug…
    STAT · 4mo agoPositive readoutPositive↗ source
  • AstraZeneca’s GLP-1 obesity pill shows 10.5% average weight loss after six months in Phase 2 trial
    AstraZeneca reported data from its Phase 2 study of a GLP-1 based oral obesity treatment. The trial showed participants lost an average of 10.5% of body weight after six months of therapy. The re…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • AstraZeneca’s oral GLP-1 candidate elecoglipron cuts weight 11% in Phase 2 obesity trial
    A Phase 2 study (VISTA) of AstraZeneca’s oral GLP‑1 molecule elecoglipron in people with obesity showed an average weight loss of 11.2 % after 36 weeks, according to data presented at the American…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Incyte to acquire Vega Therapeutics for up to $2 billion, securing late-stage von Willebrand disease drug
    Incyte announced it will purchase Vega Therapeutics, a unit of Star Therapeutics, for $1.25 billion in cash with the possibility of receiving up to $750 million more if future sales targets are met…
    BioPharma Dive · 4mo agoDealPositive↗ source